June 10, 2020 / 1:00 PM / a month ago

BRIEF-Novel Antibody Drug Conjugate Abbv-3373 Shows Improvement In Phase 2A Study Of Patients With Rheumatoid Arthritis

June 10 (Reuters) - Abbvie Inc:

* NOVEL ANTIBODY DRUG CONJUGATE ABBV-3373 SHOWS IMPROVEMENT IN DISEASE ACTIVITY IN PHASE 2A STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS

* ABBVIE - IN PHASE 2A STUDY STUDY, SAFETY PROFILE OF ABBV-3373 WAS GENERALLY SIMILAR TO KNOWN SAFETY PROFILE OF ADALIMUMAB

* ABBVIE - EVALUATIONS OF SERUM CORTISOL LEVELS OVER 12 WEEKS INDICATE ABBV-3373 SHOWED NO SYSTEMIC GLUCOCORTICOID EFFECTS

* ABBVIE - BASED ON RESULTS WILL ADVANCE DEVELOPMENT OF TNF-ADC PLATFORM IN RHEUMATOID ARTHRITIS, BEGIN CLINICAL STUDIES IN OTHER IMMUNE-MEDIATED DISEASES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below